8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 9, 2026·SEC
United Therapeutics Corporation(UTHR)Earnings, Financials & Key Ratios
UTHR•NASDAQ
19.3× P/E·Price updated Jun 19, 2026
AboutUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Show more
- Revenue$3.18B+10.6%
- EBITDA$1.6B+10.6%
- Net Income$1.33B+11.7%
- EPS (Diluted)27.86+13.1%
- Gross Margin87.92%-1.5%
- EBITDA Margin50.36%
- Operating Margin47.67%-0.4%
- Net Margin41.94%+1.0%
- ROE19.71%+2.5%
UTHR Key Insights
United Therapeutics Corporation (UTHR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 21.0%
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 32.7% free cash flow margin
- ✓Strong 5Y sales CAGR of 16.5%
- ✓Good 3Y average ROE of 19.1%
- ✓Healthy 5Y average net margin of 38.3%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when UTHR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
UTHR Price & Volume
United Therapeutics Corporation (UTHR) stock price & volume — 10-year historical chart
Loading chart...
UTHR Growth Metrics
United Therapeutics Corporation (UTHR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.06%
5 Years16.5%
3 Years18.02%
TTM5.87%
Profit CAGR
10 Years7.43%
5 Years20.99%
3 Years22.43%
TTM6.34%
EPS CAGR
10 Years8.16%
5 Years19.28%
3 Years22.92%
TTM7.94%
Return on Capital
10 Years22.55%
5 Years18.66%
3 Years20.87%
Last Year21.76%
UTHR Recent Earnings
United Therapeutics Corporation (UTHR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$5.82-16.9%
$7.00
Rev
$782M-2.0%
$797M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$7.70+8.0%
$7.13
Rev
$790M-2.8%
$813M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$7.16+3.9%
$6.89
Rev
$800M-1.9%
$815M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$6.41-12.1%
$7.29
Rev
$799M-0.4%
$802M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $5.82vs $7.00-16.9% | $782Mvs $797M-2.0% |
| Q1 2026 | Feb 25, 2026 | $7.70vs $7.13+8.0% | $790Mvs $813M-2.8% |
| Q4 2025 | Oct 29, 2025 | $7.16vs $6.89+3.9% | $800Mvs $815M-1.9% |
| Q3 2025 | Jul 30, 2025 | $6.41vs $7.29-12.1% | $799Mvs $802M-0.4% |
Based on last 12 quarters of dataView full earnings history →
UTHR Peer Comparison
United Therapeutics Corporation (UTHR) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IDYA | 2.74B | 31.23 | -24.40 | 30.24% | -62.17% | -13.96% | 0.03 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTGX | 7.26B | 112.86 | -55.05 | -89.41% | -6.48% | -17.76% | 0.02 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 MNKD | 1.22B | 3.94 | 197 | 22.23% | -6.63% | |||
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 |
Compare UTHR vs Peers
United Therapeutics Corporation (UTHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
UTHR Income Statement
United Therapeutics Corporation (UTHR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.73B | 1.63B | 1.45B | 1.48B | 1.69B | 1.94B | 2.33B | 2.88B | 3.18B | 3.17B |
Revenue Growth % | 7.91% | -5.65% | -11% | 2.38% | 13.63% | 14.88% | 20.2% | 23.63% | 10.61% | 5.87% |
Cost of Goods Sold | 105.7M | 198.7M | 117.6M | 108.1M | 122.5M | 146.7M | 257.5M | 309.7M | 384.4M | 425.3M |
COGS % of Revenue | 6.13% | 12.21% | 8.12% | 7.29% | 7.27% | 7.58% | 11.06% | 10.76% | 12.08% | - |
Gross Profit | 1.62B▲ 0% | 1.43B▼ 11.8% | 1.33B▼ 6.9% | 1.38B▲ 3.3% | 1.56B▲ 13.7% | 1.79B▲ 14.5% | 2.07B▲ 15.7% | 2.57B▲ 24.0% | 2.8B▲ 9.0% | 2.74B▲ 0% |
Gross Margin % | 93.87% | 87.79% | 91.88% | 92.71% | 92.73% | 92.42% | 88.94% | 89.24% | 87.92% | 86.58% |
Gross Profit Growth % | 6.13% | -11.76% | -6.85% | 3.31% | 13.66% | 14.5% | 15.67% | 24.04% | 8.98% | - |
Operating Expenses | 594.7M | 623.7M | 1.52B | 781.6M | 1.01B | 809.9M | 885.1M | 1.19B | 1.28B | 1.31B |
OpEx % of Revenue | 34.47% | 38.32% | 104.83% | 52.69% | 59.75% | 41.83% | 38.03% | 41.38% | 40.25% | - |
Selling, General & Admin | 330.1M | 265.8M | 336.2M | 423.9M | 467M | 487M | 477.1M | 638.6M | 731.1M | 746.5M |
SG&A % of Revenue | 19.13% | 16.33% | 23.21% | 28.58% | 27.71% | 25.15% | 20.5% | 22.19% | 22.97% | - |
Research & Development | 264.6M | 357.9M | 1.18B | 357.7M | 540.1M | 322.9M | 408M | 481M | 550M | 539.2M |
R&D % of Revenue | 15.34% | 21.99% | 81.63% | 24.12% | 32.04% | 16.68% | 17.53% | 16.72% | 17.28% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71.1M | 0 | 1000K |
Operating Income | 814.9M▲ 0% | 805.4M▼ 1.2% | -187.6M▼ 123.3% | 593.6M▲ 416.4% | 555.9M▼ 6.4% | 979.7M▲ 76.2% | 1.18B▲ 20.9% | 1.38B▲ 16.2% | 1.52B▲ 10.2% | 1.44B▲ 0% |
Operating Margin % | 47.23% | 49.48% | -12.95% | 40.02% | 32.98% | 50.6% | 50.91% | 47.86% | 47.67% | 45.34% |
Operating Income Growth % | -23.25% | -1.17% | -123.29% | 416.42% | -6.35% | 76.24% | 20.95% | 16.21% | 10.18% | - |
EBITDA | 845.9M | 841.3M | -141.7M | 643.5M | 605.8M | 1.03B | 1.24B | 1.45B | 1.6B | 1.53B |
EBITDA Margin % | 49.03% | 51.68% | -9.78% | 43.38% | 35.94% | 53.25% | 53.19% | 50.38% | 50.36% | 48.13% |
EBITDA Growth % | -22.63% | -0.54% | -116.84% | 554.13% | -5.86% | 70.19% | 20.09% | 17.07% | 10.58% | 6.95% |
D&A (Non-Cash Add-back) | 31M | 35.9M | 45.9M | 49.9M | 49.9M | 51.3M | 53.2M | 72.5M | 85.6M | 88.4M |
EBIT | 1.02B | 802.5M | -120.8M | 596.4M | 686.9M | 989M | 1.33B | 1.58B | 1.73B | 1.63B |
Net Interest Income | 1.9M | 14.7M | 0 | 5.1M | -1.9M | 12.8M | 103.4M | 156.2M | 172.5M | 166.3M |
Interest Income | 10.9M | 28.6M | 44.2M | 28.6M | 16.7M | 45.2M | 162.7M | 199.1M | 192M | 182.7M |
Interest Expense | 9M | 13.9M | 44.2M | 23.5M | 18.6M | 32.4M | 59.3M | 42.9M | 19.5M | 16.4M |
Other Income/Expense | -45.4M | -46.5M | 22.6M | 45.3M | 38M | -29.1M | 89.4M | 162M | 196.7M | 171.6M |
Pretax Income | 769.5M▲ 0% | 758.9M▼ 1.4% | -165M▼ 121.7% | 638.9M▲ 487.2% | 593.9M▼ 7.0% | 950.6M▲ 60.1% | 1.27B▲ 34.1% | 1.54B▲ 20.8% | 1.71B▲ 11.4% | 1.61B▲ 0% |
Pretax Margin % | 44.6% | 46.62% | -11.39% | 43.07% | 35.24% | 49.09% | 54.75% | 53.49% | 53.85% | 50.75% |
Income Tax | 351.6M | 169.7M | -60.5M | 124.1M | 118.1M | 223.3M | 289.5M | 343.9M | 379.2M | 321.3M |
Effective Tax Rate % | 45.69% | 22.36% | 36.67% | 19.42% | 19.89% | 23.49% | 22.72% | 22.35% | 22.12% | 19.97% |
Net Income | 417.9M▲ 0% | 589.2M▲ 41.0% | -104.5M▼ 117.7% | 514.8M▲ 592.6% | 475.8M▼ 7.6% | 727.3M▲ 52.9% | 984.8M▲ 35.4% | 1.2B▲ 21.4% | 1.33B▲ 11.7% | 1.29B▲ 0% |
Net Margin % | 24.22% | 36.2% | -7.21% | 34.71% | 28.23% | 37.56% | 42.31% | 41.53% | 41.94% | 40.61% |
Net Income Growth % | -41.45% | 40.99% | -117.74% | 592.63% | -7.58% | 52.86% | 35.4% | 21.35% | 11.68% | 6.34% |
Net Income (Continuing) | 417.9M | 589.2M | -104.5M | 514.8M | 475.8M | 727.3M | 984.8M | 1.2B | 1.33B | 1.29B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 9.31▲ 0% | 13.39▲ 43.8% | -2.39▼ 117.8% | 11.54▲ 582.8% | 10.06▼ 12.8% | 15.00▲ 49.1% | 19.81▲ 32.1% | 24.64▲ 24.4% | 27.86▲ 13.1% | 27.28▲ 0% |
EPS Growth % | -38.95% | 43.82% | -117.85% | 582.85% | -12.83% | 49.11% | 32.07% | 24.38% | 13.07% | 7.94% |
EPS (Basic) | 9.50 | 13.54 | -2.39 | 11.65 | 10.60 | 15.98 | 21.04 | 26.44 | 30.13 | - |
Diluted Shares Outstanding | 44.9M | 44M | 43.8M | 44.6M | 47.3M | 48.5M | 49.7M | 48.5M | 47.9M | 47.2M |
Basic Shares Outstanding | 44M | 43.5M | 43.8M | 44.2M | 44.9M | 45.5M | 46.8M | 45.2M | 44.3M | 43.5M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
UTHR Balance Sheet
United Therapeutics Corporation (UTHR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.45B | 1.77B | 1.86B | 2.17B | 2.32B | 3.38B | 3.55B | 3.87B | 3.7B | 2.87B |
Cash & Short-Term Investments | 927.4M | 1.42B | 1.49B | 1.83B | 1.93B | 2.84B | 2.99B | 3.27B | 1.56B | 2.15B |
Cash Only | 705.1M | 669.2M | 738.4M | 738.7M | 894.8M | 961.2M | 1.21B | 1.7B | 1.56B | 1.07B |
Short-Term Investments | 222.3M | 746.7M | 747.5M | 1.1B | 1.04B | 1.88B | 1.79B | 1.57B | 0 | 1.08B |
Accounts Receivable | 297.1M | 175.7M | 151.4M | 157.4M | 198.7M | 220.4M | 278.9M | 279.3M | 350.2M | 312M |
Days Sales Outstanding | 62.85 | 39.4 | 38.14 | 38.73 | 43.03 | 41.55 | 43.74 | 35.43 | 40.16 | 38.55 |
Inventory | 107.9M | 101M | 93.4M | 86.5M | 93.8M | 102M | 111.8M | 157.9M | 183.1M | 178.3M |
Days Inventory Outstanding | 372.6 | 185.53 | 289.89 | 292.07 | 279.49 | 253.78 | 158.47 | 186.09 | 173.86 | 151.71 |
Other Current Assets | 115.5M | 75.4M | -633.7M | 88.3M | 100.4M | 219.2M | 166.2M | 169.7M | 1.61B | 228M |
Total Non-Current Assets | 1.43B | 1.63B | 2.05B | 2.45B | 2.85B | 2.66B | 3.62B | 3.49B | 4.18B | 3.84B |
Property, Plant & Equipment | 545.7M | 699.7M | 738.5M | 731.6M | 780.9M | 861.5M | 1.05B | 1.22B | 1.73B | 1.84B |
Fixed Asset Turnover | 3.16x | 2.33x | 1.96x | 2.03x | 2.16x | 2.25x | 2.23x | 2.35x | 1.84x | 1.95x |
Goodwill | 13.7M | 31.5M | 28M | 28M | 28M | 28M | 33.7M | 32.3M | 0 | 0 |
Intangible Assets | 31.9M | 139.3M | 130.3M | 130.1M | 16.6M | 16.5M | 80.5M | 79.6M | 116.5M | 115.5M |
Long-Term Investments | 502.7M | 442.6M | 767.5M | 1.15B | 1.65B | 1.32B | 1.91B | 1.48B | 1.78B | 6.76B |
Other Non-Current Assets | 224.1M | 224.2M | 154.6M | 169.9M | 108.2M | 114.3M | 151.8M | 222.1M | 196.9M | 141.6M |
Total Assets | 2.88B▲ 0% | 3.4B▲ 18.1% | 3.91B▲ 15.1% | 4.62B▲ 17.9% | 5.17B▲ 12.0% | 6.04B▲ 16.9% | 7.17B▲ 18.6% | 7.36B▲ 2.7% | 7.88B▲ 7.0% | 6.71B▲ 0% |
Asset Turnover | 0.60x | 0.48x | 0.37x | 0.32x | 0.33x | 0.32x | 0.32x | 0.39x | 0.40x | 0.42x |
Asset Growth % | 23.81% | 18.11% | 15.07% | 17.93% | 12.01% | 16.94% | 18.57% | 2.75% | 7.01% | 14.53% |
Total Current Liabilities | 444.7M | 276.6M | 463M | 323.3M | 305.4M | 343.2M | 804.4M | 738.1M | 560.6M | 599.1M |
Accounts Payable | 8.4M | 23.1M | 9.9M | 4.1M | 3.8M | 4.1M | 5.6M | 6M | 0 | 498.3M |
Days Payables Outstanding | 29.01 | 42.43 | 30.73 | 13.84 | 11.32 | 10.2 | 7.94 | 7.07 | - | 300.01 |
Short-Term Debt | 0 | 0 | 250M | 0 | 0 | 0 | 400M | 300M | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 163.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 401.7M | 215.6M | -141.4M | 20.4M | 248M | 13M | 40.5M | 432.1M | 560.6M | 100.8M |
Current Ratio | 3.26x | 6.39x | 4.03x | 6.70x | 7.61x | 9.85x | 4.41x | 5.25x | 6.60x | 4.79x |
Quick Ratio | 3.01x | 6.03x | 3.83x | 6.44x | 7.30x | 9.55x | 4.28x | 5.03x | 6.28x | 4.50x |
Cash Conversion Cycle | 406.44 | 182.49 | 297.31 | 316.96 | 311.19 | 285.13 | 194.27 | 214.45 | - | -109.75 |
Total Non-Current Liabilities | 313.7M | 316.6M | 670M | 896.5M | 904.8M | 904.6M | 377.8M | 181.9M | 223.2M | 214M |
Long-Term Debt | 250M | 250M | 600M | 800M | 800M | 800M | 300M | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 63.7M | 66.6M | 70M | 96.5M | 104.8M | 104.6M | 77.8M | 181.9M | 223.2M | 214M |
Total Liabilities | 777.6M | 612.4M | 1.13B | 1.22B | 1.21B | 1.25B | 1.18B | 920M | 783.8M | 813.1M |
Total Debt | 250M | 250M | 850M | 800M | 800M | 800M | 700M | 300M | 0 | 0 |
Net Debt | -455.1M | -419.2M | 111.6M | 61.3M | -94.8M | -161.2M | -507.7M | -1.4B | -1.56B | -1.07B |
Debt / Equity | 0.12x | 0.09x | 0.31x | 0.24x | 0.20x | 0.17x | 0.12x | 0.05x | - | 0.00x |
Debt / EBITDA | 0.30x | 0.30x | - | 1.24x | 1.32x | 0.78x | 0.57x | 0.21x | - | 0.00x |
Net Debt / EBITDA | -0.54x | -0.50x | - | 0.10x | -0.16x | -0.16x | -0.41x | -0.96x | -0.97x | -0.70x |
Interest Coverage | 113.60x | 57.73x | -2.73x | 25.38x | 36.93x | 30.52x | 22.49x | 36.87x | 88.89x | 99.37x |
Total Equity | 2.1B▲ 0% | 2.79B▲ 32.7% | 2.78B▼ 0.3% | 3.4B▲ 22.1% | 3.96B▲ 16.6% | 4.8B▲ 21.2% | 5.98B▲ 24.8% | 6.44B▲ 7.7% | 7.1B▲ 10.1% | 5.9B▲ 0% |
Equity Growth % | 12.87% | 32.68% | -0.29% | 22.11% | 16.6% | 21.16% | 24.77% | 7.67% | 10.12% | 30.74% |
Book Value per Share | 46.81 | 63.38 | 63.48 | 76.13 | 83.70 | 98.90 | 120.42 | 132.87 | 148.15 | 125.02 |
Total Shareholders' Equity | 2.1B | 2.79B | 2.78B | 3.4B | 3.96B | 4.8B | 5.98B | 6.44B | 7.1B | 5.9B |
Common Stock | 700K | 700K | 700K | 700K | 700K | 700K | 700K | 800K | 800K | 800K |
Retained Earnings | 2.85B | 3.43B | 3.33B | 3.84B | 4.32B | 5.04B | 6.03B | 7.22B | 8.56B | 8.83B |
Treasury Stock | -2.58B | -2.58B | -2.58B | -2.58B | -2.58B | -2.58B | -2.58B | -3.47B | -4.26B | -5.44B |
Accumulated OCI | -19.6M | -7.9M | -14.2M | -14.2M | -23M | -55.5M | -12.8M | -3.4M | 900K | -10.2M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
UTHR Cash Flow Statement
United Therapeutics Corporation (UTHR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 474.2M | 778.4M | -206.6M | 755.7M | 598.2M | 802.5M | 978M | 1.33B | 1.56B | 1.56B |
Operating CF Margin % | 27.49% | 47.82% | -14.26% | 50.95% | 35.49% | 41.45% | 42.02% | 46.12% | 49.05% | - |
Operating CF Growth % | -26.32% | 64.15% | -126.54% | 465.78% | -20.84% | 34.15% | 21.87% | 35.7% | 17.64% | 33.5% |
Net Income | 417.9M | 589.2M | -104.5M | 514.8M | 475.8M | 727.3M | 984.8M | 1.2B | 1.33B | 1.29B |
Depreciation & Amortization | 31M | 35.9M | 45.9M | 49.9M | 49.9M | 51.3M | 53.2M | 72.5M | 85.6M | 88.4M |
Stock-Based Compensation | 73.5M | -26.4M | 45.4M | 163.8M | 138.5M | 106.8M | 39.1M | 144M | 147.7M | 115.9M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 97.7M | 123.6M |
Other Non-Cash Items | 30.2M | 55.3M | -15.1M | -35.9M | 108.2M | 58.3M | -1.3M | -24.3M | 2M | 120.1M |
Working Capital Changes | -78.4M | 124.4M | -178.3M | 63.1M | -174.2M | -141.2M | -97.8M | -60.2M | -106.4M | -172M |
Change in Receivables | -82.7M | 121.4M | 24.4M | -6M | -41.3M | -21.7M | -58.5M | -400K | -70.9M | 10M |
Change in Inventory | -500K | 9.3M | 12.9M | 10.3M | -7.5M | -13.4M | -13.6M | -46.9M | -52.6M | -81.5M |
Change in Payables | 66.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 97.9M | 85.2M |
Cash from Investing | -835.6M | -820.6M | -335.4M | -738.5M | -486.9M | -811.5M | -719.6M | 417.2M | -551.3M | 357.1M |
Capital Expenditures | -86.3M | -184.4M | -83.7M | -59.3M | -120.8M | -138.8M | -230.4M | -246.5M | -520.5M | -546.4M |
CapEx % of Revenue | 5% | 11.33% | 5.78% | 4% | 7.17% | 7.17% | 9.9% | 8.57% | 16.35% | 17.24% |
Acquisitions | -60.3M | -129.1M | -20.5M | 0 | 0 | -1.5M | -89.2M | -30.5M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 8.3M | -46M | 0 | 2.4M | 0 | 3.5M | -23M | -28.5M | 1.85B | 1.85B |
Cash from Financing | 43.3M | 6.3M | 611.2M | -16.9M | 44.8M | 75.4M | -11.9M | -1.25B | -1.15B | -2.54B |
Debt Issued (Net) | 250M | 0 | 600M | -50M | 0 | 0 | -100M | -400M | -300M | -200M |
Equity Issued (Net) | -250M | 0 | -2.1M | -3.7M | -10.8M | -11.4M | -13.8M | -1.01B | -816.9M | -2.24B |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -250M | 0 | -2.1M | -3.7M | -10.8M | -11.4M | -13.8M | -1.01B | -1B | -2.5B |
Other Financing | 43.3M | 6.3M | 13.3M | 36.8M | 55.6M | 86.8M | 101.9M | 157.4M | -33.1M | -97.6M |
Net Change in Cash | -317.9M▲ 0% | -35.9M▲ 88.7% | 69.2M▲ 292.8% | 300K▼ 99.6% | 156.1M▲ 51933.3% | 66.4M▼ 57.5% | 246.5M▲ 271.2% | 489.5M▲ 98.6% | -140.1M▼ 128.6% | -825.7M▲ 0% |
Free Cash Flow | 387.9M▲ 0% | 594M▲ 53.1% | -290.3M▼ 148.9% | 696.4M▲ 339.9% | 477.4M▼ 31.4% | 663.7M▲ 39.0% | 747.6M▲ 12.6% | 1.08B▲ 44.5% | 1.04B▼ 3.7% | 1.02B▲ 0% |
FCF Margin % | 22.48% | 36.49% | -20.04% | 46.95% | 28.32% | 34.28% | 32.12% | 37.55% | 32.7% | 32.08% |
FCF Growth % | -35.39% | 53.13% | -148.87% | 339.89% | -31.45% | 39.02% | 12.64% | 44.54% | -3.69% | -9.9% |
FCF per Share | 8.64 | 13.50 | -6.63 | 15.61 | 10.09 | 13.68 | 15.04 | 22.28 | 21.73 | 21.54 |
FCF Conversion (FCF/Net Income) | 1.13x | 1.32x | 1.98x | 1.47x | 1.26x | 1.10x | 0.99x | 1.11x | 1.17x | 0.79x |
Interest Paid | 7.5M | 9.4M | 41M | 20.7M | 16.2M | 29.1M | 56M | 40.2M | 13.5M | 8.1M |
Taxes Paid | 346.9M | 102.7M | 120.2M | 92.8M | 153.3M | 275.7M | 332.5M | 400.6M | 313.3M | 312.8M |
UTHR Key Ratios
United Therapeutics Corporation (UTHR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 21.08% | 24.1% | -3.75% | 16.67% | 12.94% | 16.61% | 18.27% | 19.23% | 19.71% | 19.24% |
Return on Invested Capital (ROIC) | 49.17% | 30.08% | -5.35% | 14.03% | 11.39% | 17.29% | 17.58% | 19.63% | 21.5% | 20.15% |
Gross Margin | 93.87% | 87.79% | 91.88% | 92.71% | 92.73% | 92.42% | 88.94% | 89.24% | 87.92% | 86.58% |
Net Margin | 24.22% | 36.2% | -7.21% | 34.71% | 28.23% | 37.56% | 42.31% | 41.53% | 41.94% | 40.61% |
Debt / Equity | 0.12x | 0.09x | 0.31x | 0.24x | 0.20x | 0.17x | 0.12x | 0.05x | - | 0.00x |
Interest Coverage | 113.60x | 57.73x | -2.73x | 25.38x | 36.93x | 30.52x | 22.49x | 36.87x | 88.89x | 99.37x |
FCF Conversion | 1.13x | 1.32x | 1.98x | 1.47x | 1.26x | 1.10x | 0.99x | 1.11x | 1.17x | 0.79x |
Revenue Growth | 7.91% | -5.65% | -11% | 2.38% | 13.63% | 14.88% | 20.2% | 23.63% | 10.61% | 5.87% |
Related:UTHR Dividend History·UTHR Revenue History·UTHR Price History·UTHR P/E History·UTHR Financial Ratios·UTHR Institutional Holders
UTHR SEC Filings & Documents
United Therapeutics Corporation (UTHR) SEC filings — annual & quarterly reports (10-K, 10-Q)
UTHR Frequently Asked Questions
United Therapeutics Corporation (UTHR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
United Therapeutics Corporation (UTHR) reported $3.17B in revenue for fiscal year 2025. This represents a 3169700% increase from $0.1M in 1998.
United Therapeutics Corporation (UTHR) grew revenue by 10.6% over the past year. This is steady growth.
Yes, United Therapeutics Corporation (UTHR) is profitable, generating $1.29B in net income for fiscal year 2025 (41.9% net margin).
Dividend & Returns
United Therapeutics Corporation (UTHR) has a return on equity (ROE) of 19.7%. This is reasonable for most industries.
United Therapeutics Corporation (UTHR) generated $1.02B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.